Fate awarded $15M CIRM CLIN2 grant to fund Phase 2 RECLAIM-LN trial of FT819
Fate received a $15.0 million CIRM CLIN2 grant to support its Phase 2 RECLAIM-LN trial of FT819.Key Highlights:Original SEC Filing: FATE THERAPEUTICS INC [ FATE ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the sourc…